CA2960324A1 - Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents - Google Patents

Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents Download PDF

Info

Publication number
CA2960324A1
CA2960324A1 CA2960324A CA2960324A CA2960324A1 CA 2960324 A1 CA2960324 A1 CA 2960324A1 CA 2960324 A CA2960324 A CA 2960324A CA 2960324 A CA2960324 A CA 2960324A CA 2960324 A1 CA2960324 A1 CA 2960324A1
Authority
CA
Canada
Prior art keywords
mmol
mixture
methyl
compound
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2960324A
Other languages
English (en)
French (fr)
Inventor
Hartmut Beck
Tobias THALER
Raimund Kast
Daniel Meibom
Mark Meininghaus
Carsten TERJUNG
Martina Delbeck
Klemens Lustig
Uwe Muenster
Britta Olenik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of CA2960324A1 publication Critical patent/CA2960324A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/50—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4
    • C07D215/52—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/58—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems with hetero atoms directly attached to the ring nitrogen atom
    • C07D215/60—N-oxides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2960324A 2014-09-09 2015-09-07 Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents Abandoned CA2960324A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14184040 2014-09-09
EP14184040.5 2014-09-09
PCT/EP2015/070318 WO2016037954A1 (de) 2014-09-09 2015-09-07 Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung

Publications (1)

Publication Number Publication Date
CA2960324A1 true CA2960324A1 (en) 2016-03-17

Family

ID=51492240

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2960324A Abandoned CA2960324A1 (en) 2014-09-09 2015-09-07 Substituted n,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents

Country Status (6)

Country Link
US (2) US10189788B2 (enExample)
EP (1) EP3191452A1 (enExample)
JP (1) JP6618530B2 (enExample)
CN (1) CN107074773A (enExample)
CA (1) CA2960324A1 (enExample)
WO (1) WO2016037954A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3191452A1 (de) * 2014-09-09 2017-07-19 Bayer Pharma Aktiengesellschaft Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung
US10117864B2 (en) * 2015-03-18 2018-11-06 Bayer Pharma Aktiengesellschaft Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
TWI770157B (zh) * 2017-04-10 2022-07-11 德商拜耳廠股份有限公司 經取代之n-芳基乙基-2-胺基喹啉-4-甲醯胺及其用途
US11136296B2 (en) 2017-04-10 2021-10-05 Bayer Aktiengesellschaft Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof
US12569481B2 (en) 2020-06-12 2026-03-10 Vanderbilt University Methods of treatment for gastrointestinal motility disorders
JP2023541601A (ja) 2020-09-10 2023-10-03 プレシリックス・ナームローゼ・ベンノートシヤープ Ｆａｐに対する抗体フラグメント
WO2023203135A1 (en) 2022-04-22 2023-10-26 Precirix N.V. Improved radiolabelled antibody
AU2023264245A1 (en) 2022-05-02 2024-12-19 Precirix N.V. Pre-targeting
TW202504604A (zh) 2023-07-26 2025-02-01 荷蘭商菲林公司 小分子前列腺素ｆ受體拮抗劑
WO2025189066A1 (en) * 2024-03-08 2025-09-12 Athira Pharma, Inc. Modulators of g protein-coupled receptor 55 (gpr55)

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK282721B6 (sk) 1994-05-27 2002-11-06 Smithkline Beecham S.P.A. Nepeptidové NK3 antagonistické látky, spôsob ich výroby, farmaceutické prostriedky s ich obsahom a ich použitie
IT1270615B (it) 1994-07-14 1997-05-07 Smithkline Beecham Farma Uso di derivati di chinolina
AR004735A1 (es) 1995-11-24 1999-03-10 Smithkline Beecham Spa Quinoleina 4-amido sustituida, un procedimiento para su preparacion, una composicion farmaceutica que los contiene y el uso de los mismos para lapreparacion de un medicamento.
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
CN1660811A (zh) * 2004-02-27 2005-08-31 中国科学院上海药物研究所 1，4－二取代苯类化合物及其制备方法和用途
EP1856099A2 (en) * 2005-03-03 2007-11-21 Sirtris Pharmaceuticals, Inc. Acridine and quinoline derivatives as sirtuin modulators
AU2009249237A1 (en) 2008-05-19 2009-11-26 Schering Corporation Bicyclic heterocycle derivatives and use thereof as GPR119 modulators
EP2415755A4 (en) 2009-03-31 2012-09-19 Renascience Co Ltd INHIBITOR AGENT OF PLASMINOGEN ACTIVATOR INHIBITOR 1
JP2011042643A (ja) 2009-07-24 2011-03-03 Bayer Cropscience Ag 殺虫性カルボキサミド類
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EA201390060A1 (ru) 2010-07-09 2013-07-30 Байер Интеллектуэль Проперти Гмбх Аннелированные пиримидины и триазины и их применение для лечения и/или профилактики сердечно-сосудистых заболеваний
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2013074059A2 (en) 2010-11-05 2013-05-23 Regents Of The University Of Minnesota Cytosine deaminase modulators for enhancement of dna transfection
CA2867527A1 (en) 2012-05-03 2013-11-07 Takeda Gmbh Novel ep2 receptor agonists
TWI572597B (zh) * 2012-06-29 2017-03-01 美國禮來大藥廠 二甲基－苯甲酸化合物
AU2014209107B2 (en) 2013-01-28 2018-04-12 Viamet Pharmaceuticals (NC), Inc. Metalloenzyme inhibitor compounds
ME03398B (me) * 2013-12-17 2020-01-20 Lilly Co Eli Spojevi dimetilbenzojeve kiseline
EP3191452A1 (de) * 2014-09-09 2017-07-19 Bayer Pharma Aktiengesellschaft Substituierte n,2-diarylchinolin-4-carboxamide und ihre anti-inflammatorische verwendung

Also Published As

Publication number Publication date
EP3191452A1 (de) 2017-07-19
US10479765B2 (en) 2019-11-19
US10189788B2 (en) 2019-01-29
US20190002409A1 (en) 2019-01-03
US20170260140A1 (en) 2017-09-14
JP2017526701A (ja) 2017-09-14
WO2016037954A1 (de) 2016-03-17
JP6618530B2 (ja) 2019-12-11
CN107074773A (zh) 2017-08-18

Similar Documents

Publication Publication Date Title
US10479765B2 (en) Substituted N,2-diarylquinoline-4-carboxamides and the use thereof as anti-inflammatory agents
US10117864B2 (en) Substituted N-bicyclo-2-aryl-quinolin-4-carboxamides and use thereof
JP6367421B2 (ja) 二環で置換されたウラシル類およびそれの使用
CA3007724C (en) 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders
US9695131B2 (en) Substituted uracils as chymase inhibitors
IL271117A (en) Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders
JP2026506002A (ja) Ｓｏｓ１阻害剤及び抗がん薬を含む、がんの処置のための医薬組成物
CA3031136A1 (en) Substituted imidazo[1,2-a]pyridin-3-yl compounds and their use for the treatment and/or prevention of respiratory disorders
BR112020007967A2 (pt) imidazopiridina amidas substituídas e uso das mesmas
CN105793267B (zh) 环状噻吩并尿嘧啶甲酰胺类及其用途
JP2016536362A (ja) 置換されているウラシル類及びそれらの使用
WO2017153234A1 (de) Substituierte n-cyclo-2-arylchinolin-4-carboxamide und ihre verwendung
CA3030204A1 (en) 7-substituted 1-pyridyl-naphthyridine-3-carboxylic acid amides and use thereof
WO2017153231A1 (de) Substituierte n-cyclo-2-arylisochinolinon-4-carboxamide und ihre verwendung
US11337973B2 (en) Substituted [1,2,4]triazolo[4,3-A]pyrazines as prolyl endopeptidase inhibitors
US11136296B2 (en) Substituted N-arylethyl-2-arylquinoline-4-carboxamides and use thereof

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20211130